|
• Patients of both sexes undergoing a primary elective median abdominal incision
|
• Patients with a known history of adhesion or peritonitis
|
|
• Age equal or greater than 18 years
|
• Patients with a known sensitivity to polyvinylalcohol or carboxy-methylcellulose
|
|
• Written informed consent
|
• Simultaneous participation in another clinical trial with interfering end-points
|
|
• Expected incison length ≥15 cm
|
• Emergency surgery
|
|
• Expected survival time more than12 months
|
• Patients with peritoneal carcinosis or peritoneal dialysis
|
|
• For female adults of reproductive potential: negative pregnancy test at visit 1 and sufficient contraception from time of written consent up to at least 4 months
|
• Patients with systemic immunsuppression (e.g. hydrocortisone >50 mg per daily, other immunsuppressants like Azathropin, Mycophenolatmofetil, Ciclosporin, Everolimus, Methotrexat ect.), chemotherapy or radiotherapy within the last 2 weeks prior surgery
|
| |
• Patients with ascites >200 ml
|
| |
• ASA > 3
|
| |
• Patients with intra-abdominal abscess or other intra-abdominal infection
|
| |
• Renal impairment (Creatinine >1.3 mg/ml)
|
| |
• Pregnant or breast-feeding women
|
| |
• Lack of compliance
|
| |
• Surgical procedures or patients which require insertion more than 2 intra abdominal drains
|
